SCHEMBL4280341

SCHEMBL4280341

CCc1ccc(Cl)cc1I

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 4/20 0.40
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 3/20 0.38
KCNH2 Q12809 2/20 0.38
NLRP1 Q9C000 1/20 0.38
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
CTRC Q99895 1/20 0.38
FLT1 P17948 1/20 0.36
FLT4 P35916 1/20 0.36
KDR P35968 1/20 0.36
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
SLC22A1 O15245 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4608241 0.79 IDO1 (0.41) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL31454441 0.79 IDO1 (0.41) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL3782085 0.78 IDO1 (0.44) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL2997812 0.77 CYP2A6 (0.44) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL1995097 0.77 IDO1 (0.40) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL1197989 0.77 IDO1 (0.41) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL31454434 0.77 IDO1 (0.41) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL155790 0.76 IDO1 (0.60) IDO1MAPK1CYP3A4CYP1A2CYP2C9
SCHEMBL13019662 0.76 TTR (0.36) IDO1SLC6A4CTRC
SCHEMBL1627266 0.75 KMT2A (0.46) LMNAHTTSMN1; SMN2MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
EP-3636636-B1 PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL FUNGICIDE MITSUI CHEMICALS AGRO INC (JP) 2022-07-06 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20200288710-A1 SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-09-17 US disclosed
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-20 US disclosed
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-20 US disclosed
WO-2014019908-A2 SUBSTITUTED PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2014-02-06 WO disclosed
WO-2013014039-A1 ALKYNYL SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASES INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-01-31 WO disclosed
WO-2012143248-A1 SUBSTITUTED PYRIMIDINYL-PYRROLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-26 WO disclosed
WO-2012139930-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-18 WO disclosed
WO-2012139930-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-10-18 WO disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 IDO1 1076/4885MAPK1 2160/4885CYP3A4 2694/4885
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT IDO1 1564/4885MAPK1 3470/4885CYP3A4 4728/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 IDO1 1076/4885MAPK1 2160/4885CYP3A4 2694/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 IDO1 1076/4885MAPK1 2160/4885CYP3A4 2694/4885
US-20140051708-A1 PYRAZOLYL-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS MAP3K1, MAP3K20, MAP3K6 IDO1 3164/4885MAPK1 225/4885CYP3A4 3722/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT IDO1 1550/4885MAPK1 3449/4885CYP3A4 4816/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH IDO1 1123/4885MAPK1 2932/4885CYP3A4 4043/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 IDO1 1216/4885MAPK1 2554/4885CYP3A4 3719/4885
US-20200288710-A1 SUBSTITUTED SULPHONAMIDES FOR CONTROLLING ANIMAL PESTS DDT, MPST, STOM IDO1 2158/4885MAPK1 3581/4885CYP3A4 1836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.